PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Mount Sinai and City of Hope scientists first to demonstrate a combination treatment can increase human insulin-producing cells in vivo

Research published in Science Translational Medicine advances therapies to regenerate beta cells as a potential new treatment for diabetes

2024-07-10
(Press-News.org) NEW YORK and LOS ANGELES — In preclinical studies, a team of researchers from Mount Sinai Health System in New York City and City of Hope in Los Angeles report new findings on a therapeutic combination that regenerated human insulin-producing beta cells, providing a possible new treatment for diabetes. The findings were published today in Science Translational Medicine.  

This work, led by Andrew F. Stewart, MD, Irene and Dr. Arthur M. Fishberg Professor of Medicine and Director of the Mount Sinai Diabetes, Obesity and Metabolism Institute, began at the Icahn School of Medicine at Mount Sinai in 2015. The studies were a team effort. Adolfo Garcia-Ocaña, PhD, formerly a professor at Mount Sinai and who is now at City of Hope, a leading research center for diabetes and one of the largest cancer research and treatment organizations in the United States, and is the Ruth B. and Robert K. Lanman Chair in Gene Regulation and Drug Discovery Research and chair of the Department of Molecular & Cellular Endocrinology, and his research team designed the studies and performed the novel, extensive and detailed animal transplant and drug treatment models using beta cells from donors. Final studies took place at City of Hope in 2023.

For the study, the natural product harmine, which is found in some plants, was combined with a widely used class of type 2 diabetes therapy called GLP1 receptor agonists. Researchers transplanted a small number of human beta cells into mice that had no immune system and that also served as a standard model of type 1 and type 2 diabetes; these mice were treated with the combination therapy and their diabetes was rapidly reversed. Strikingly, human beta cell numbers increased by 700 percent over three months with this drug combination. 

“This is the first time scientists have developed a drug treatment that is proven to increase adult human beta cell numbers in vivo. This research brings hope for the use of future regenerative therapies to potentially treat the hundreds of millions of people with diabetes,” said Dr. Garcia-Ocaña, the paper’s corresponding author.

“It has been remarkable to watch this story unfold over the past 15 years,” said Dr. Stewart, who, along with Peng Wang, PhD, Professor of Medicine (Endocrinology, Diabetes and Bone Disease) at Icahn Mount Sinai, conceived of and performed the initial high-throughput drug screen that led to the discovery of harmine described in Nature Medicine in 2015. “The steady progression from the most basic human beta cell biology, through robotic drug screening and now moving to human studies, illustrates the essential role for physician-scientists in academia and pharma.”

Growing New Beta Cells

More than 10 percent of the world’s adult population has diabetes, a disease defined by high blood sugar levels. In both type 1 and type 2 diabetes, a reduction in both the quantity and quality of insulin-producing beta cells causes high blood sugar. Unfortunately, none of the many commonly used diabetes therapies are able to increase human beta cell numbers, and therefore cannot completely reverse diabetes.

Fortunately, most people with diabetes have some residual beta cells, which is what inspired the research team to search for ways to restore their numbers. The team had previously shown that several different inhibitors of an enzyme in beta cells called DYRK1A can induce the proliferation of adult human beta cells in a tissue culture dish for a few days. But prior to this study, no one had shown the ability to expand human beta cells numbers in vivo in human islet grafts used in an animal model over many months.

To accurately measure the mass of human beta cells in the islet grafts, the team turned to Sarah A. Stanley, MBBCh, PhD, Associate Professor of Medicine (Endocrinology, Diabetes and Bone Disease), and Neuroscience, at Icahn Mount Sinai. Using an advanced laser microscopy tool called iDISCO+ that effectively makes biological tissue transparent, Dr. Stanley saw that beta cell mass was dramatically increased through mechanisms that included enhanced proliferation, function, and survival of the human beta cells. The technology allowed for accurate and rigorous quantitative assessment of engrafted human beta cells for the first time.

Translating Results to the Clinic

The Mount Sinai team recently completed a phase 1 clinical trial of harmine in healthy volunteers to test its safety and tolerability. At the same time, Robert J. DeVita, PhD, Professor of Pharmacological Sciences and Director of the Marie-Josée and Henry R. Kravis Drug Discovery Institute at Mount Sinai, has developed next-generation DYRK1A inhibitors. Mount Sinai is conducting studies to test these in humans for potential toxicity risks and estimate dosing for clinical trials, and is planning to initiate first-in-human trials with independent research teams next year. Mount Sinai owns an extensive patent portfolio covering these technologies.

Researchers also want to address the fact that in patients with type 1 diabetes, the immune system will continue to kill new beta cells. At City of Hope, Dr. Garcia-Ocaña and colleague Alberto Pugliese, MD, Samuel Rahbar Chair in Diabetes & Drug Discovery, chair of the Department of Diabetes Immunology, and director of The Wanek Family Project for Type 1 Diabetes within the Arthur Riggs Diabetes & Metabolism Research Institute, plan to test inducers of beta cell regeneration together with immunomodulators that regulate the immune system. Their goal is for the combination to allow new beta cells to thrive and improve insulin levels.   

“Our studies pave the way for moving DYRK1A inhibitors into human clinical trials and it's very exciting to be close to seeing this novel treatment used in patients,” Dr. Garcia-Ocaña said. “There is nothing like this available to patients right now.”

The work outlined in the Science Translational Medicine paper was funded by grants from the National Institutes of Health (NIH), the National Institute of Diabetes Digestive and Kidney Disease, and BreakthroughT1D (formerly JDRF); as well as from philanthropic donations to Mount Sinai, support from The Wanek Family Project for Type 1 Diabetes at City of Hope, and additional generous philanthropic gifts.

Other critical members of the team include Mount Sinai’s Carolina Rosselot, PhD; Yansui Li, PhD; and Alexandra Alvarsson, PhD. Additional City of Hope authors on the paper are Geming Lu, MD, assistant research professor, and Randy Kang, BS, senior research associate, who are both members of Dr. Garcia-Ocaña’s lab.

Drs. Stewart and DeVita are named co-inventors on patent applications for DYRK1A inhibitors, such as harmine, for the treatment of diabetes. These patent applications are filed through the Icahn School of Medicine at Mount Sinai and are currently unlicensed.

# # #

About City of Hope

City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.

 

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2023-2024. 

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube. 

END



ELSE PRESS RELEASES FROM THIS DATE:

City of Hope and Mount Sinai scientists first to demonstrate a combination treatment can increase human insulin-producing cells in vivo

City of Hope and Mount Sinai scientists first to demonstrate a combination treatment can increase human insulin-producing cells in vivo
2024-07-10
LOS ANGELES and NEW YORK — In preclinical studies, a team of researchers from City of Hope® in Los Angeles and Mount Sinai Health System in New York reports new findings on a therapeutic combination that regenerated human insulin-producing beta cells, providing a possible new treatment for diabetes. The findings were published today in Science Translational Medicine.   This work, led by Andrew F. Stewart, M.D., Irene and Dr. Arthur M. Fishberg Professor of Medicine and Director of the Mount Sinai Diabetes, Obesity and Metabolism Institute, began at the Icahn School of Medicine at Mount Sinai in 2015. The studies were a team effort. Adolfo ...

New Co-STAR receptor shows promise treating cancers in laboratory study

New Co-STAR receptor shows promise treating cancers in laboratory study
2024-07-10
Using genetic engineering techniques, investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy have designed a novel type of cell to recognize and fight cancer. To produce the cells, called Co-STAR (Co-stimulatory Synthetic T-cell receptor and Antigen Receptor) cells, the researchers combined genetic components of four types of cells that the body normally uses to defend against invaders to make ...

Novel genome editing approach restores hearing in adult preclinical models with genetic deafness

2024-07-10
The study also looked at safety of the AAV-mediated genome editing approach and found it had a good safety profile that includes little off-target effect and no detectable long-term integration of the AAV vector in the genome. “Our research suggested minimal potential risk and supports the feasibility of future clinical applications in humans,” said Wenliang Zhu, PhD, and physician-scientist Wan Du, MD, PhD, members of Chen’s lab at Mass Eye and Ear and first authors on the paper. The study, led by Zheng-Yi Chen, DPhil, an associate scientist in the Eaton-Peabody Laboratories at Mass Eye and Ear (a member of the ...

Rice’s Omid Veiseh elected to the Controlled Release Society College of Fellows

Rice’s Omid Veiseh elected to the Controlled Release Society College of Fellows
2024-07-10
HOUSTON – (July 10, 2024) – The Controlled Release Society (CRS), the premier international, multidisciplinary society dedicated to the science and technology of drug delivery, has elected Rice University bioengineer Omid Veiseh to its College of Fellows. The recognition is a prestigious acknowledgement of “outstanding and sustained contributions in the field of delivery science and technology,” according to the organization website. “I am deeply honored to be elected to the CRS College ...

Bringing quantum tools to high school classrooms

Bringing quantum tools to high school classrooms
2024-07-10
More than 70 high school students and science teachers gathered at Young Middle School in Arlington this summer to learn about quantum information science (QIS). The annual workshop and camp are part of a national pilot program called Quantum for All led by Karen Jo Matsler, assistant professor in practice and master teacher in the UTeach program at The University of Texas at Arlington. “Just the word ‘quantum’ scares people, which is why many teachers and school administrators ...

Novel pre-treatment process enhances PFAs removal from drinking water

Novel pre-treatment process enhances PFAs removal from drinking water
2024-07-10
In a groundbreaking effort to tackle the pervasive issue of PFAS contamination in drinking water, a research team at New Jersey Institute of Technology has received funding from the Bureau of Reclamation's Desalination and Water Purification Research program. This highly competitive grant, awarded to only eight projects out of over eighty applicants, supports their innovative project titled "Enhanced Coagulation for the Removal of Per- and Polyfluoroalkyl Substances using Hydrophobic Ion Pairing Approach Project." Arjun Venkatesan, associate ...

NASA’s Hubble finds strong evidence for intermediate-mass black hole in Omega Centauri

NASA’s Hubble finds strong evidence for intermediate-mass black hole in Omega Centauri
2024-07-10
Most known black holes are either extremely massive, like the supermassive black holes that lie at the cores of large galaxies, or relatively lightweight, with a mass of under 100 times that of the Sun. Intermediate-mass black holes (IMBHs) are scarce, however, and are considered rare "missing links" in black hole evolution. Now, an international team of astronomers has used more than 500 images from NASA's Hubble Space Telescope — spanning two decades of observations — to search for evidence of an intermediate-mass black hole by following the motion of seven ...

The Society for Nutrition Education and Behavior (SNEB) issues its position on how to address emergency food and nutrition needs in disaster preparedness

2024-07-10
Philadelphia, July 10, 2024 – Despite escalating disaster frequency and severity, guidance for addressing emergency food and nutrition needs is limited. However, existing literature offers insights on how to effectively address emergency food and nutrition assistance. A recent position paper issued by the Society for Nutrition Education and Behavior (SNEB) in the Journal of Nutrition Education and Behavior, published by Elsevier, states that for effective recovery from and resilience to disasters, it is essential that impacted individuals and communities have access to safe, nutritious, and culturally and contextually appropriate foods and beverages, and receive emergency-related ...

Tackling the challenge of coca plant ID: wild vs cultivated for cocaine

2024-07-10
A new paper published today in Molecular Biology and Evolution reveals that it's not as straightforward as it might seem. Despite decades of data collection by the United Nations Office on Drugs and Crime (UNODC), which has been valuable to monitor changes in areas occupied by illegal coca plantations in South America, there is no reliable scientific method to distinguish between different types of coca plants. South American coca plants have been essential to Andean and Amazonian communities for at least 8,000 years. It is within these communities that they are thought to have evolved from wild to domesticated coca plants. Their ...

BESSY II shows how solid-state batteries degrade

BESSY II shows how solid-state batteries degrade
2024-07-10
Solid-state batteries have several advantages: they can store more energy and are safer than batteries with liquid electrolytes. However, they do not last as long and their capacity decreases with each charge cycle. But it doesn't have to stay that way: Researchers are already on the trail of the causes. In the journal ACS Energy Letters, a team from HZB and Justus-Liebig-Universität, Giessen, presents a new method for precisely monitoring electrochemical reactions during the operation of a solid-state battery using photoelectron spectroscopy at BESSY II. The results ...

LAST 30 PRESS RELEASES:

Generative AI tools like Pix2Pix–BicycleGAN are revolutionizing landscape design by enhancing masterplan generation and rendering

Expanding APAC presence, Insilico Medicine seals strategic collaboration on AI-driven mash therapy development with Korean Biotech Therasid Bioscience

When it comes to butterflies, people prefer pretty ones. That’s a problem for scientists.

UBC Okanagan study raises concerns about partner violence in queer relationships

Human-infecting parasite produces sterile soldiers like ants and termites

The unintended consequences of success against malaria

Taco-shaped arthropod from Royal Ontario Museum’s Burgess Shale fossils gives new insights into the history of the first mandibulates

Butterflies accumulate enough static electricity to attract pollen without contact, new research finds

Eyes for Love: Searching for light and a mate in the deep, dark sea, male dragonfishes grow larger eyes than the females they seek

PNNL scientists tap nation’s fastest computers to explore critical science questions

Peri-operative care of transgender and gender-diverse individuals: new guidance for clinicians and departments published

Clinical psychologist’s book addresses largely ignored problem: social anxiety

Researchers leveraging AI to train (robotic) dogs to respond to their masters

Drawing water from dry air

Combining trapped atoms and photonics for new quantum devices

A new way to make element 116 opens the door to heavier atoms

New genetic tool could identify drug targets for diseases associated with metabolic dysfunction

Plant Biologist Siobhan Brady named HHMI Investigator

Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy

Large language models don’t behave like people, even though we may expect them to

NREL researchers highlight opportunities for manufacturing perovskite solar panels with a long-term vision

Top Medicare advantage plans less available in disadvantaged areas

Better carbon storage better carbon storage with stacked geology with stacked geology

Sharp temperature reduction for quantum dots in polymer by highly efficient heat dissipation pathways

UAF researcher creates way to detect elusive volcanic vibrations

Lissajous pattern multi-pass cell: Enhancing high sensitivity and simultaneous dual-gas LITES sensing

Asexual reproduction usually leads to a lack of genetic diversity. Not for these ants.

Mini lungs make major COVID-19 discoveries possible

Exploratory analysis associates HIV drug abacavir with elevated cardiovascular disease risk in large global trial

Control of light–matter interactions in two-dimensional materials with nanoparticle-on-mirror structures

[Press-News.org] Mount Sinai and City of Hope scientists first to demonstrate a combination treatment can increase human insulin-producing cells in vivo
Research published in Science Translational Medicine advances therapies to regenerate beta cells as a potential new treatment for diabetes